| 【英語タイトル】Global Mental Health Clinical Trials Market Size study & Forecast, by Phase (Phase I, Phase II, Phase III, Phase IV), by Study Design (Interventional, Observational, Expanded Access) by Sponsor (Pharmaceutical & Biopharmaceutical Companies, Government Agencies, Others), by Disorder (Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation and dissociative disorders, Schizophrenia, Others) and Regional Analysis, 2022-2029
|
 | ・商品コード：BZW23MA016
・発行会社（調査会社）：Bizwit Research & Consulting
・発行日：2023年4月17日
・ページ数：約200
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：アメリカ、カナダ、イギリス、ドイツ、フランス、スペイン、イタリア、中国、インド、日本、オーストラリア、韓国、ブラジル、メキシコ、中東
・産業分野：医療
|
◆販売価格オプション
（消費税別）
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
|
❖ レポートの概要 ❖
Bizwit Research社の本調査資料では、2021年にXX億ドルであった世界のメンタルヘルス臨床試験市場規模が、2022年〜2029年にかけて年平均XX%で成長すると予測しています。本資料は、メンタルヘルス臨床試験の世界市場について市場実態を明らかにするとともに、今後の動向を展望したレポートです。エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、フェーズ別（フェーズI、フェーズII、フェーズIII、フェーズIV）分析、研究デザイン別（介入、観察、拡張アクセス）分析、提供者別（製薬・バイオ医薬品、政府機関、その他）分析、疾患別（不安障害、うつ病、双極性感情障害、解離性障害、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他地域）分析、競争分析、調査プロセスなどの項目で構成されています。また、主要参入企業として、ICON Plc.、Eli Lilly and Company、Caidya、Syneous Health、Novo Nordisk AS 、Pharmaceutical Product Development, LLC、Parexel International Corporation、Corcept Therapeutics Incorporated (Corcept)、Labcorp Drug Development、IQVIA, Inc.などの情報が含まれています。
・エグゼクティブサマリー
・市場定義・範囲
・市場動向
・産業分析
・リスク分析（新型コロナウイルス感染症の影響）
・世界のメンタルヘルス臨床試験市場規模：フェーズ別
- フェーズIにおける市場規模
- フェーズIIにおける市場規模
- フェーズIIIにおける市場規模
- フェーズIVにおける市場規模
・世界のメンタルヘルス臨床試験市場規模：研究デザイン別
- 介入における市場規模
- 観察における市場規模
- 拡張アクセスにおける市場規模
・世界のメンタルヘルス臨床試験市場規模：提供者別
- 製薬・バイオ医薬品における市場規模
- 政府機関における市場規模
- その他提供者における市場規模
・世界のメンタルヘルス臨床試験市場規模：疾患別
- 不安障害における市場規模
- うつ病における市場規模
- 極性感情障害における市場規模
- 解離性障害における市場規模
- その他疾患における市場規模
・世界のメンタルヘルス臨床試験市場規模：地域別
- 北米のメンタルヘルス臨床試験市場規模
- ヨーロッパのメンタルヘルス臨床試験市場規模
- アジア太平洋のメンタルヘルス臨床試験市場規模
- 中南米のメンタルヘルス臨床試験市場規模
- その他地域のメンタルヘルス臨床試験市場規模
・競争分析
・調査プロセス |
Global Mental Health Clinical Trials Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. This are the clinics which deals with mental health problems. Throughout the course of the projection period, it is predicted that the global market for mental health clinical trials would expand significantly. The incidence of mental health illnesses, public awareness of mental health conditions, and increased funding from government agencies, businesses, hospitals, and universities are the main reasons driving the market’s expansion. Moreover, rising number of mental illness and initiative by key market players are creating lucrative growth opportunity for the market over the forecast period.
Significant disruptions in thought, behavior, or emotional regulation characterize mental illnesses. According to a recent WHO report, 1 in every 8 people worldwide will have a mental condition in 2022. The two most prevalent mental illnesses, sadness, and anxiety, affected 970 million individuals worldwide in 2019.Worry, excessive fear, and accompanying behavioral abnormalities are hallmarks of anxiety disorders. According to 2019 WHO estimate, 58.0 million of the 301.0 million people with anxiety disorders are children and adolescents. There are numerous varieties of anxiety disorders, including generalized anxiety disorder, panic disorder, and social anxiety disorder. According to a scientific analysis by the WHO, the Covid-19 pandemic increased the prevalence of anxiety and depression globally by 25%. Stress brought on by the pandemic’s social isolation is a significant factor. Depression and anxiety are caused by a variety of fears, including those of illness, pain, loneliness, money worries, and mourning following a loss. However, the high cost of Mental Health Clinical Trials stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Mental Health Clinical Trials Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Due to factors similar to increased R&D spending, supportive government policies, and growth in the use of innovative technologies in clinical trials, North America is predicted to have the largest market share throughout the projection period. Clinicaltrials.org reports that from 2019 to 2021, 52% of all registered clinical trials for depression would be conducted in the region. Also, from 2019 to 2021, the region’s trial percentage will rise from 45.9% to 50.9%. Along with this, Asia-Pacific is growing with the fastest CAGR over the forecast period owing to the rising number of clinical trials.
Major market player included in this report are:
ICON Plc.
Eli Lilly and Company
Caidya
Syneous Health
Novo Nordisk AS
Pharmaceutical Product Development, LLC
Parexel International Corporation
Corcept Therapeutics Incorporated (Corcept)
Labcorp Drug Development
IQVIA, Inc.
Recent Developments in the Market:
In September 2022, the launch of Epic’s Life Sciences division broadens its efforts to reunite the fragmented elements of the healthcare system. The goals of the program is to include facilitating the recruitment of research participants, accelerating the development of novel treatments for providers, and increasing access to clinical trials for underrepresented populations, pharmaceutical firms, and medical device manufacturers.
Global Mental Health Clinical Trials Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Study Design, Sponsor, Disorder, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Study Design offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Phase:
Phase I
Phase II
Phase III
Phase IV
By Study Design:
Interventional
Observational
Expanded Access
By Sponsor:
Pharmaceutical & Biopharmaceutical Companies
Government Agencies
Others
By Disorder:
Anxiety Disorders
Depression
Bipolar affective disorder
Dissociation and dissociative disorders
Schizophrenia
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Mental Health Clinical Trials Market, by Region, 2019-2029 (USD Billion)
1.2.2. Mental Health Clinical Trials Market, by Study Design, 2019-2029 (USD Billion)
1.2.3. Mental Health Clinical Trials Market, by Sponsor, 2019-2029 (USD Billion)
1.2.4. Mental Health Clinical Trials Market, by Disorder, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Mental Health Clinical Trials Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Mental Health Clinical Trials Market Dynamics
3.1. Mental Health Clinical Trials Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Increasing government funding
3.1.1.2. Growing number of clinical trials
3.1.2. Market Challenges
3.1.2.1. High Cost of Mental Health Clinical Trials
3.1.3. Market Opportunities
3.1.3.1. Rising number of mental illnesses
3.1.3.2. Rising initiatives by the key market players
Chapter 4. Global Mental Health Clinical Trials Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Investment Adoption Model
4.5. Analyst Recommendation & Conclusion
4.6. Top investment opportunity
4.7. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Mental Health Clinical Trials Market, by Phase
6.1. Market Snapshot
6.2. Global Mental Health Clinical Trials Market by Phase, Performance – Potential Analysis
6.3. Global Mental Health Clinical Trials Market Estimates & Forecasts by Phase 2019-2029 (USD Billion)
6.4. Mental Health Clinical Trials Market, Sub Segment Analysis
6.4.1. Phase I
6.4.2. Phase II
6.4.3. Phase III
6.4.4. Phase IV
Chapter 7. Global Mental Health Clinical Trials Market, by Study Design
7.1. Market Snapshot
7.2. Global Mental Health Clinical Trials Market by Study Design, Performance – Potential Analysis
7.3. Global Mental Health Clinical Trials Market Estimates & Forecasts by Study Design 2019-2029 (USD Billion)
7.4. Mental Health Clinical Trials Market, Sub Segment Analysis
7.4.1. Interventional
7.4.2. Observational
7.4.3. Expanded Access
Chapter 8. Global Mental Health Clinical Trials Market, by Sponsor
8.1. Market Snapshot
8.2. Global Mental Health Clinical Trials Market by Sponsor, Performance – Potential Analysis
8.3. Global Mental Health Clinical Trials Market Estimates & Forecasts by Sponsor 2019-2029 (USD Billion)
8.4. Mental Health Clinical Trials Market, Sub Segment Analysis
8.4.1. Pharmaceutical & Biopharmaceutical Companies
8.4.2. Government Agencies
8.4.3. Others
Chapter 9. Global Mental Health Clinical Trials Market, by Disorder
9.1. Market Snapshot
9.2. Global Mental Health Clinical Trials Market by Disorder, Performance – Potential Analysis
9.3. Global Mental Health Clinical Trials Market Estimates & Forecasts by Disorder 2019-2029 (USD Billion)
9.4. Mental Health Clinical Trials Market, Sub Segment Analysis
9.4.1. Anxiety Disorders
9.4.2. Depression
9.4.3. Bipolar affective disorder
9.4.4. Dissociation and dissociative disorders
9.4.5. Schizophrenia
9.4.6. Others
Chapter 10. Global Mental Health Clinical Trials Market, Regional Analysis
10.1. Mental Health Clinical Trials Market, Regional Market Snapshot
10.2. North America Mental Health Clinical Trials Market
10.2.1. U.S. Mental Health Clinical Trials Market
10.2.1.1. Phase breakdown estimates & forecasts, 2019-2029
10.2.1.2. Study Design breakdown estimates & forecasts, 2019-2029
10.2.1.3. Sponsor breakdown estimates & forecasts, 2019-2029
10.2.1.4. Disorder breakdown estimates & forecasts, 2019-2029
10.2.2. Canada Mental Health Clinical Trials Market
10.3. Europe Mental Health Clinical Trials Market Snapshot
10.3.1. U.K. Mental Health Clinical Trials Market
10.3.2. Germany Mental Health Clinical Trials Market
10.3.3. France Mental Health Clinical Trials Market
10.3.4. Spain Mental Health Clinical Trials Market
10.3.5. Italy Mental Health Clinical Trials Market
10.3.6. Rest of Europe Mental Health Clinical Trials Market
10.4. Asia-Pacific Mental Health Clinical Trials Market Snapshot
10.4.1. China Mental Health Clinical Trials Market
10.4.2. India Mental Health Clinical Trials Market
10.4.3. Japan Mental Health Clinical Trials Market
10.4.4. Australia Mental Health Clinical Trials Market
10.4.5. South Korea Mental Health Clinical Trials Market
10.4.6. Rest of Asia Pacific Mental Health Clinical Trials Market
10.5. Latin America Mental Health Clinical Trials Market Snapshot
10.5.1. Brazil Mental Health Clinical Trials Market
10.5.2. Mexico Mental Health Clinical Trials Market
10.6. Rest of The World Mental Health Clinical Trials Market
Chapter 11. Competitive Intelligence
11.1. Top Market Strategies
11.2. Company Profiles
11.2.1. ICON Plc.
11.2.1.1. Key Information
11.2.1.2. Overview
11.2.1.3. Financial (Subject to Data Availability)
11.2.1.4. Product Summary
11.2.1.5. Recent Developments
11.2.2. Eli Lilly and Company
11.2.3. Caidya
11.2.4. Syneous Health
11.2.5. Novo Nordisk AS
11.2.6. Pharmaceutical Product Development, LLC
11.2.7. Parexel International Corporation
11.2.8. Corcept Therapeutics Incorporated (Corcept)
11.2.9. Labcorp Drug Development
11.2.10. IQVIA, Inc.
Chapter 12. Research Process
12.1. Research Process
12.1.1. Data Mining
12.1.2. Analysis
12.1.3. Market Estimation
12.1.4. Validation
12.1.5. Publishing
12.2. Research Attributes
12.3. Research Assumption
